Agenus (AGEN) Releases Earnings Results, Beats Expectations By $0.42 EPS

Agenus (NASDAQ:AGEN) issued its earnings results on Thursday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.42, Fidelity Earnings reports. The firm had revenue of $8.61 million for the quarter, compared to analysts’ expectations of $9.03 million.

NASDAQ AGEN traded down $0.02 on Friday, reaching $2.86. The company had a trading volume of 77,495 shares, compared to its average volume of 1,446,751. The stock has a market cap of $401.43 million, a PE ratio of -1.98 and a beta of 1.96. Agenus has a 1 year low of $1.54 and a 1 year high of $3.88.

A number of research firms have weighed in on AGEN. BidaskClub upgraded Agenus from a “strong sell” rating to a “sell” rating in a report on Tuesday. ValuEngine upgraded Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. Finally, B. Riley began coverage on Agenus in a report on Monday, April 22nd. They issued a “buy” rating and a $5.00 price target for the company.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Amalgamated Bank purchased a new position in Agenus in the 4th quarter worth approximately $30,000. Two Sigma Securities LLC purchased a new position in Agenus in the 4th quarter worth approximately $31,000. Legal & General Group Plc boosted its holdings in Agenus by 47.7% in the 4th quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 7,002 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of Agenus by 80,579.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 19,339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Agenus by 272.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 23,493 shares in the last quarter. Hedge funds and other institutional investors own 28.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Agenus (AGEN) Releases Earnings Results, Beats Expectations By $0.42 EPS” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/10/agenus-agen-releases-earnings-results-beats-expectations-by-0-42-eps.html.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Further Reading: P/E Growth (PEG)

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.